Navigation Links
Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer
Date:12/7/2009

PRINCETON, N.J., Dec. 7 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, announced today that Stephen Kasay has joined the Company as Chief Information Officer.

In his role, Steve will have global responsibility for the Company's corporate information technology function including strategy development and execution and optimization of the Company's technology infrastructure, software and data assets.

"We are delighted to have Steve Kasay join PharmaNet Development Group," commented Jeffrey P. McMullen, president and chief executive officer. "With extensive experience in the pharmaceutical and CRO industry, Steve has the proven executive leadership and expertise needed to support clinical development and laboratory services and our data centers in North America, Europe and Asia."

Mr. Kasay has over twenty years of experience providing direction to information technology (IT) departments in global pharmaceutical companies and clinical research organizations. His accomplishments include the strategic assessment and consolidation of data, the successful implementation of software and infrastructure assets to enhance productivity, the establishment of global IT governance processes, and the development of relationships and communication practices with business partners to continually improve efficiencies and client service.

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees and more than 43 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com.


Contact: Anne-Marie Hess
Phone: (609) 951-6842
Email: ahess@pharmanet.com

SOURCE PharmaNet Development Group, Inc.


'/>"/>
SOURCE PharmaNet Development Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. EnVivo Pharmaceuticals Names Stephen DiPalma Chief Financial Officer
2. BioNeutral Groups CEO, Stephen Browand and Chief Scientist, Dr. Andrew Kielbania to Appear on WVOX 1460 AM In Focus Radio Show Hosted by Dr. Dan Miller
3. Kendle Appoints Stephen Cutler, PhD Senior Vice President and Chief Operating Officer
4. Biomodels Expands Efforts in Cancer Supportive Care, Pulmonary Fibrosis; Preclinical Research Organization Names Dr. Stephen T. Sonis as Partner
5. Cequent Names F. Stephen Laroux, Ph.D., Director, Immunology and Inflammatory Diseases
6. Stephen H. Friend, MD, PhD to Keynote at Defined Healths 9th Annual Therapeutic Insight Conference
7. Dr. John Stephen Osika, HIV/AIDS and Infectious Disease Expert, Joins Abt Associates
8. Genomic Health to Present at Stephens Fall Investment Conference
9. Neurofocus Appoints Stephen Kosslyn to Its Advisory Board
10. US Oncology Appoints Stephen Smith Vice President/General Manager Research and Personalized Science Services
11. BioNeutral Laboratories Announces the Appointment of Stephen Browand as a Director to Head Military, Homeland Security and Governmental Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
(Date:6/23/2016)... -- Amgen (NASDAQ: AMGN ) today announced a ... sciences incubator to accelerate the development of new therapies ... QB3@953 was created to help high-potential life science and ... stage organizations - access to laboratory infrastructure. ... "Amgen Golden Ticket" awards, providing each winner with one ...
(Date:6/22/2016)... , June 22, 2016 Research and ... Global Markets" report to their offering. ... billion in 2014 from $29.3 billion in 2013. The market is ... of 13.8% from 2015 to 2020, increasing from $50.6 billion in ... projected product forecasts during the forecast period (2015 to 2020) are ...
Breaking Biology Technology:
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):